Skip to main content
. 2021 Dec 2;4(12):e2136823. doi: 10.1001/jamanetworkopen.2021.36823

Figure 2. Overall Survival for Patients Receiving Nivolumab Plus Ipilimumab Combination Therapy, by Sex.

Figure 2.

Median survival was reached for female patients receiving combination therapy (10.2 months [95% CI, 4.6-23.9 months]), while more than 50% of male patients receiving combination therapy survived by the end of the study period (75 of 125 [60.0%]).